I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc ...
I assigned a Hold rating to ImmunityBio, Inc. (IBRX) stock back in September last year in a note for Seeking Alpha, and prior to that, a Hold rating in April 2025, and a Buy rating in December 2024.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...
Shares of biopharma outfit ImmunityBio (NASDAQ: IBRX) are rising firmly again today, following through on last week's effort to rekindle the erratic rally that's been underway since early January. As ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, ...
We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results